<DOC>
	<DOCNO>NCT02263079</DOCNO>
	<brief_summary>This randomize , control , parallel group , open-label multicenter study evaluate efficacy safety combination pegylated interferon alfa-2A ( Pegasys ) plus lamivudine entecavir compare untreated control group participant HBeAg positive CHB immune tolerant phase .</brief_summary>
	<brief_title>A Study Pegylated Interferon Alfa-2A Combination With Lamivudine Entecavir Compared With Untreated Control Group Children With Hepatitis B Envelope Antigen ( HBeAg ) -Positive Chronic Hepatitis B ( CHB ) Immune-Tolerant Phase</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Positive HBsAg HBeAg 6 month prior baseline Detectable HBVDNA ( &gt; 20,000 IU/mL ) measure polymerization chain reaction ( PCR ) hybridization least 2 occasion least one month apart late determination obtain less equal ( &lt; /= ) 42 day prior baseline Compensated liver disease ( ChildPugh Class A clinical classification ) Either Liver biopsy perform within 2 year prior baseline show minimal fibrosis ( Liver Biopsy Scores stable normal ALT level ( less equal upper limit normal [ ULN ] ) 6 month lead baseline ( include two separate occasion least 1 month apart 6 month prior baseline ) . Screening ALT level must normal ( &lt; /= ULN ) OR Stable normal ALT level ( &lt; /= ULN ) , 1 year lead baseline ( include three separate occasion least 1 month apart 1 year prior baseline ) sign hepatocellular carcinoma ( HCC ) , advanced fibrosis/cirrhosis , splenomegaly liver abdominal ultrasound screening . Screening ALT level must normal ( &lt; /= ULN ) Participants receive investigational drug license treatment anti HBV activity ( Exception : Participants limit [ &lt; /= 7day ] course acyclovir herpetic lesion 1 month study baseline visit exclude ) Participants participate clinical trial receive investigational drug within 6 month prior baseline Known hypersensitivity interferon ( IFN ) , pegylated interferonalfa2a lamivudine entecavir Positive test result screen hepatitis A virus Immunoglobulin M ( IgM ) antibody ( Ab ) , antihepatitis C virus ( HCV ) Ab , anti hepatitis D ( HDV ) Ab antihuman immunodeficiency virus ( HIV ) Ab Decompensated liver disease ( e.g. , ChildPugh Class B C clinical classification clinical evidence ascites varix ) Advanced fibrosis cirrhosis Suspicion HCC liver abdominal ultrasound ( patient liver abdominal ultrasound within 6 month prior baseline ) History evidence medical condition associate chronic liver disease CHB include metabolic liver disease hemochromatosis , Wilson 's disease alpha1 antitrypsin deficiency Active substance abuse within 6 month prior screen Sexually active female childbearing potential sexually active male willing utilize reliable contraception treatment 90 day follow end treatment Females pregnant breastfeeding ( female childbearing potential positive urine serum pregnancy test result within 24 hour baseline exclude )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>